Alexandre LeBeaut serves as an Independent Director for CYTEA BIO and Neurenati Therapeutics, focusing on innovative therapeutic developments in oncology and rare diseases. As the Chairman of the Board at Versameb AG and an Independent Board Member for ImmunoRx Pharma, LeBeaut brings extensive experience in biotechnology and immunotherapy, having previously held similar positions at OSE Immunotherapeutics, Calypso Biotech, and Object Pharma, Inc. LeBeaut was also the CEO of the Institute for Advanced Clinical Trials for Children and served as an Independent Director at Vifor Pharma. With a passion for improving patients' lives, LeBeaut is actively seeking executive and non-executive board roles in R&D. LeBeaut holds an MD in Pediatrics from Université Paris Cité and is pursuing a degree in Finance for Executives from INSEAD.